BR112015003591A2 - - Google Patents
Info
- Publication number
- BR112015003591A2 BR112015003591A2 BR112015003591A BR112015003591A BR112015003591A2 BR 112015003591 A2 BR112015003591 A2 BR 112015003591A2 BR 112015003591 A BR112015003591 A BR 112015003591A BR 112015003591 A BR112015003591 A BR 112015003591A BR 112015003591 A2 BR112015003591 A2 BR 112015003591A2
- Authority
- BR
- Brazil
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/073283 WO2014079495A1 (en) | 2012-11-21 | 2012-11-21 | Methods for the manufacture of proteolytically processed polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112015003591A2 true BR112015003591A2 (enExample) | 2015-02-20 |
| BR112015003591A8 BR112015003591A8 (pt) | 2017-08-22 |
| BR112015003591B1 BR112015003591B1 (pt) | 2022-02-01 |
Family
ID=47216287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015003591-4A BR112015003591B1 (pt) | 2012-11-21 | 2012-11-21 | Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado |
| BR112015010550A BR112015010550A8 (pt) | 2012-11-21 | 2013-11-21 | Usos de lys-c, métodos para fabricação de um polipeptídeo proteoliticamente processado, para fabricação de um polipeptídeo proteoliticamente ativo, para avaliação para um inibidor do polipeptídeo proteoliticamente ativo, e para geração de fragmentos de polipeptídeo, composições, polipeptídeo proteoliticamente ativo, uso do mesmo, molécula de ácido nucléico, vetor, célula e uso de um polipeptídeo processado |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015010550A BR112015010550A8 (pt) | 2012-11-21 | 2013-11-21 | Usos de lys-c, métodos para fabricação de um polipeptídeo proteoliticamente processado, para fabricação de um polipeptídeo proteoliticamente ativo, para avaliação para um inibidor do polipeptídeo proteoliticamente ativo, e para geração de fragmentos de polipeptídeo, composições, polipeptídeo proteoliticamente ativo, uso do mesmo, molécula de ácido nucléico, vetor, célula e uso de um polipeptídeo processado |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10087432B2 (enExample) |
| JP (3) | JP6156954B2 (enExample) |
| KR (4) | KR20180077343A (enExample) |
| CN (5) | CN120118892A (enExample) |
| AR (3) | AR093578A1 (enExample) |
| AU (2) | AU2012395188B2 (enExample) |
| BR (2) | BR112015003591B1 (enExample) |
| CA (2) | CA3062150C (enExample) |
| IN (1) | IN2015DN01449A (enExample) |
| MX (3) | MX363788B (enExample) |
| RU (2) | RU2673910C2 (enExample) |
| TW (5) | TW201839134A (enExample) |
| UA (2) | UA111795C2 (enExample) |
| WO (2) | WO2014079495A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10792344B2 (en) * | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| RU2673910C2 (ru) | 2012-11-21 | 2018-12-03 | Ипсен Байоинновейшн Лимитед | Способ производства протеолитически процессированного полипептида |
| WO2015088477A1 (en) * | 2013-12-09 | 2015-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Peptide substrates recognizable by type e botulinum neurotoxin |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| KR101882461B1 (ko) * | 2014-05-29 | 2018-07-27 | 주식회사 프로셀테라퓨틱스 | 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도 |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3263710A1 (en) * | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| CN117959415A (zh) | 2016-09-13 | 2024-05-03 | 阿勒根公司 | 非蛋白质梭菌毒素组合物 |
| JP7524058B2 (ja) * | 2017-10-13 | 2024-07-29 | ウィスコンシン アラムニ リサーチ ファンデーション | ボツリヌス神経毒素ａサブタイプ６および薬理学的使用方法 |
| EP3752128B1 (de) * | 2018-02-16 | 2025-01-15 | preclinics discovery GmbH | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
| WO2020222315A1 (ko) * | 2019-04-29 | 2020-11-05 | 주식회사 바이오셀트란 | 피부 또는 세포 투과능이 우수한 피부 주름 개선 또는 치료용 조성물 |
| GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| EP4121100A2 (en) | 2020-03-16 | 2023-01-25 | Ipsen Biopharm Limited | Modified botulinum neurotoxin for treating limb spasticity |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| US20250129354A1 (en) | 2021-09-16 | 2025-04-24 | Ipsen Biopharm Limited | Modified Bont/A for Use in the Treatment of Cervical Dystonia |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| WO2023047127A1 (en) | 2021-09-23 | 2023-03-30 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
| CA3234608A1 (en) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202307439D0 (en) | 2023-05-18 | 2023-07-05 | Ipsen Biopharm Ltd | Treatment of a headache disorder with botylinum neurotoxin a |
| WO2025093845A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines |
| WO2025093844A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| DE102025101336A1 (de) * | 2024-01-19 | 2025-07-24 | Abbvie Inc. | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
| US8153397B2 (en) * | 1993-09-21 | 2012-04-10 | The United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| US7227010B2 (en) * | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| AU2907695A (en) * | 1994-08-08 | 1996-03-07 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
| US6967088B1 (en) | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| DE19856897A1 (de) | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
| US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| US7740868B2 (en) * | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
| US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
| KR100876060B1 (ko) * | 1999-08-25 | 2008-12-26 | 알러간, 인코포레이티드 | 활성화가능한 재조합 신경독 |
| AU2001286727A1 (en) | 2000-08-24 | 2002-03-04 | Coulter Pharmaceutical, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
| TW526437B (en) * | 2001-08-08 | 2003-04-01 | Macronix Int Co Ltd | Photolithography rework analysis method and system |
| US20040013687A1 (en) * | 2002-05-31 | 2004-01-22 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| US20040018589A1 (en) * | 2002-07-25 | 2004-01-29 | Jun Zhong | Method for producing biologically active botulinum neurotoxins through recombinant DNA technique |
| WO2005016232A2 (en) | 2002-08-01 | 2005-02-24 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| AU2003272800A1 (en) * | 2002-10-01 | 2004-04-23 | University Of Maryland | Methods for identifying inhibitors of botulinum neurotoxins |
| US20080171347A1 (en) | 2003-04-11 | 2008-07-17 | Atassi M Zouhair | Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides |
| WO2005030119A2 (en) | 2003-04-11 | 2005-04-07 | Allergan, Inc. | Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
| WO2005035730A2 (en) * | 2003-10-07 | 2005-04-21 | Allergan, Inc. | Dna sequences of the botulinum neurotoxin complex of type a-hall (allergan) strain |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| EP1773874B1 (en) * | 2004-08-04 | 2012-10-24 | Allergan, Inc. | Optimizing expression of active botulinum toxin type a |
| EP1784420B1 (en) * | 2004-09-01 | 2008-12-03 | Allergan, Inc. | Degradable clostridial toxins |
| DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| DE102005002978B4 (de) * | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| US8052979B2 (en) * | 2005-03-15 | 2011-11-08 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US7465457B2 (en) * | 2005-04-14 | 2008-12-16 | Wisconsin Alumni Research Foundation | Method for preparing botulinum neurotoxin type A light chain |
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| ATE463506T1 (de) * | 2005-09-19 | 2010-04-15 | Allergan Inc | Mit clostriedientoxin aktivierbare clostridientoxine |
| US9072735B2 (en) | 2005-10-03 | 2015-07-07 | Yong Qian | Proteinases destroy cancer tumor's solid structure and kill cancer cells locally |
| US7464917B2 (en) * | 2005-10-07 | 2008-12-16 | Appiled Materials, Inc. | Ampoule splash guard apparatus |
| DE102005051789B4 (de) * | 2005-10-28 | 2014-08-07 | Toxogen Gmbh | Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| CA2658260A1 (en) * | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| KR100677871B1 (ko) * | 2006-09-11 | 2007-02-02 | 주식회사 메가젠 | 골충진재 성형 장치 및 골충진재 성형 방법 |
| WO2008152429A1 (en) * | 2007-06-14 | 2008-12-18 | Health Protection Agency | Chemically modified peptides with improved immunogenicity |
| US8486422B2 (en) * | 2007-07-26 | 2013-07-16 | Allergan, Inc. | Methods of activating clostridial toxins |
| EP2023327A1 (en) * | 2007-07-27 | 2009-02-11 | Foxboro Eckardt Gmbh | Operation voltage controller and method for controlling an operation voltage controller |
| EP2211890A1 (en) * | 2007-10-23 | 2010-08-04 | Allergan, Inc. | Methods of treating urogenital-neurological disorders using modified clostridial toxins |
| US20090104234A1 (en) * | 2007-10-23 | 2009-04-23 | Allergan, Inc. | Methods of treating chronic neurogenic inflammation using modified clostridial toxins |
| BR122012027456A2 (pt) * | 2008-03-14 | 2015-07-14 | Allergan Inc | Composição farmacêutica compreendendo sorotipo de neurotoxina botulínica a |
| WO2010014854A2 (en) | 2008-07-31 | 2010-02-04 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| US8492109B2 (en) * | 2009-01-20 | 2013-07-23 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
| BRPI1008885B1 (pt) * | 2009-02-19 | 2021-09-28 | Merz Pharma Gmbh & Co. Kgaa | Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição |
| MX2011009621A (es) * | 2009-03-13 | 2011-12-16 | Allergan Inc | Celulas utiles para ensayos de actividad del serotipo a de la toxina botulinica baados en inmunoensayos. |
| CA2757637C (en) * | 2009-04-27 | 2017-10-24 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities |
| US20100303783A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases |
| US20100303757A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases |
| US8586329B2 (en) * | 2009-07-02 | 2013-11-19 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxins exhibiting shortened biological activity |
| ES2676277T3 (es) * | 2009-10-16 | 2018-07-18 | Biomadison, Inc. | Células modificadas genéticamente para el ensayo de transferencia de energía por resonancia con el resto del sustrato de sinaptobrevina |
| US10246492B2 (en) * | 2009-10-16 | 2019-04-02 | Biomadison, Inc. | Botulinum assay with synaptobrevin substrate moiety |
| AU2010353292A1 (en) | 2009-12-16 | 2012-07-12 | Allergan, Inc. | Modified Clostridial toxins comprising an integrated protease cleavage site-binding domain |
| US20130245227A1 (en) * | 2010-01-15 | 2013-09-19 | Allergan, Inc. | Methods of activating clostridial toxins |
| MX2012008650A (es) * | 2010-01-25 | 2012-11-23 | Allergan Inc | Metodos de conversion intracelular de proteinas monocatenarias en su formula bicatenaria. |
| AT511002A1 (de) * | 2011-02-08 | 2012-08-15 | Univ Innsbruck | Verfahren zur verformung von cellulosecarbamat und produkte, die nach diesem verfahren hergestellt werden |
| US20120207734A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases |
| WO2012112432A1 (en) * | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases |
| GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| EP2524963B1 (en) * | 2011-05-19 | 2018-10-31 | Ipsen Bioinnovation Limited | Methods for the manufacture of proteolytically processed polypeptides |
| HK1199890A1 (en) * | 2011-11-09 | 2015-07-24 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxins exhibiting shortened biological activity |
| EP2823053B1 (en) * | 2012-03-07 | 2017-08-23 | Merz Pharma GmbH & Co. KGaA | Means and methods for determining neurotoxin activity based on a modified luciferase |
| KR101729710B1 (ko) * | 2012-04-09 | 2017-04-24 | 서울대학교산학협력단 | 물에 안정하게 분산되는 멜라닌 나노입자를 포함하는 핵자기 공명 영상 조영제 |
| EP3372239B1 (en) * | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| US20150232828A1 (en) * | 2012-08-20 | 2015-08-20 | Merz Pharma Gmbh & Co. Kgaa | Method for the manufacturing of recombinant proteins harbouring an n-terminal lysine |
| RU2673910C2 (ru) * | 2012-11-21 | 2018-12-03 | Ипсен Байоинновейшн Лимитед | Способ производства протеолитически процессированного полипептида |
| SI2922822T1 (sl) * | 2012-11-22 | 2017-04-26 | Sanofi | Postopek priprave derivatov feniloksimetil-nitro-imidazola in njihova uporaba |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| US11897921B2 (en) * | 2014-12-09 | 2024-02-13 | New York University | Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain |
| CN107624115B (zh) * | 2015-03-16 | 2021-10-26 | 加州理工学院 | 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法 |
| GB201505306D0 (en) * | 2015-03-27 | 2015-05-13 | Ipsen Biopharm Ltd | Chimeric polypeptides |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| CA3024331A1 (en) * | 2016-05-16 | 2017-11-23 | President And Fellows Of Harvard College | Method for purification and activation of botulinum neurotoxin |
| PL3481852T3 (pl) * | 2016-07-08 | 2023-07-24 | Children's Medical Center Corporation | Nowa neurotoksyna botulinowa i jej pochodne |
-
2012
- 2012-11-21 RU RU2015107240A patent/RU2673910C2/ru active
- 2012-11-21 KR KR1020187018705A patent/KR20180077343A/ko not_active Ceased
- 2012-11-21 KR KR1020157004071A patent/KR102083371B1/ko active Active
- 2012-11-21 CN CN202510029795.7A patent/CN120118892A/zh active Pending
- 2012-11-21 BR BR112015003591-4A patent/BR112015003591B1/pt active IP Right Grant
- 2012-11-21 CA CA3062150A patent/CA3062150C/en active Active
- 2012-11-21 CN CN202010161444.9A patent/CN111454931A/zh active Pending
- 2012-11-21 US US14/423,222 patent/US10087432B2/en active Active
- 2012-11-21 UA UAA201502409A patent/UA111795C2/uk unknown
- 2012-11-21 MX MX2015002390A patent/MX363788B/es active IP Right Grant
- 2012-11-21 WO PCT/EP2012/073283 patent/WO2014079495A1/en not_active Ceased
- 2012-11-21 AU AU2012395188A patent/AU2012395188B2/en active Active
- 2012-11-21 JP JP2015535999A patent/JP6156954B2/ja active Active
- 2012-11-21 MX MX2019000098A patent/MX381995B/es unknown
- 2012-11-21 CN CN201280075874.2A patent/CN104870468B/zh active Active
- 2012-11-21 CA CA2880897A patent/CA2880897C/en active Active
- 2012-11-21 KR KR1020177012803A patent/KR102083373B1/ko active Active
-
2013
- 2013-11-21 KR KR1020157016356A patent/KR20150085844A/ko not_active Ceased
- 2013-11-21 TW TW107123545A patent/TW201839134A/zh unknown
- 2013-11-21 CN CN202010771933.6A patent/CN112048009A/zh active Pending
- 2013-11-21 WO PCT/GB2013/053072 patent/WO2014080206A1/en not_active Ceased
- 2013-11-21 TW TW102142485A patent/TW201439322A/zh unknown
- 2013-11-21 TW TW107123546A patent/TWI713862B/zh active
- 2013-11-21 JP JP2015543521A patent/JP2015536654A/ja active Pending
- 2013-11-21 UA UAA201506009A patent/UA117231C2/uk unknown
- 2013-11-21 CN CN201380060742.7A patent/CN104797595B/zh active Active
- 2013-11-21 TW TW107123543A patent/TW201839133A/zh unknown
- 2013-11-21 RU RU2015124069A patent/RU2015124069A/ru not_active Application Discontinuation
- 2013-11-21 BR BR112015010550A patent/BR112015010550A8/pt not_active Application Discontinuation
- 2013-11-21 TW TW107123542A patent/TWI709649B/zh active
- 2013-11-21 MX MX2015006324A patent/MX2015006324A/es unknown
- 2013-11-21 AR ARP130104298A patent/AR093578A1/es active IP Right Grant
-
2015
- 2015-02-20 IN IN1449DEN2015 patent/IN2015DN01449A/en unknown
-
2017
- 2017-08-30 AU AU2017221793A patent/AU2017221793B2/en active Active
-
2018
- 2018-08-20 US US16/105,120 patent/US10808236B2/en active Active
- 2018-11-05 JP JP2018208320A patent/JP2019030333A/ja active Pending
-
2020
- 2020-02-06 AR ARP200100322A patent/AR118019A2/es unknown
- 2020-07-14 US US16/928,107 patent/US11441141B2/en active Active
-
2022
- 2022-07-15 US US17/812,800 patent/US20230015772A1/en active Pending
- 2022-11-09 AR ARP220103075A patent/AR127620A2/es unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: IPSEN BIOINNOVATION LIMITED (GB) |
|
| B25G | Requested change of headquarter approved |
Owner name: IPSEN BIOINNOVATION LIMITED (GB) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/11/2012, OBSERVADAS AS CONDICOES LEGAIS. |